Search research articles
Contact Us
Filters
Showing results (11-20 of 54) with videos related to
Page
of 6
Sort By:
Immunology
|
January 16, 2010
The melanocortin receptor agonist NDP-MSH impairs the allostimulatory function of dendritic cells
La'Verne P Rennalls, Thomas Seidl, James M G Larkin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2002
Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study
Ronald Bukowski, Marc S Ernstoff, Martin E Gore, et al.
Melanoma Research
|
March 29, 2006
Anti-alphaGal-dependent complement-mediated cytotoxicity in metastatic melanoma
James M G Larkin, Peter J Norsworthy, Roger P A'Hern, et al.
Gynecologic Oncology
|
July 7, 2007
Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials
Michelle L Harrison, Martin E Gore, David Spriggs, et al.
BJU International
|
December 17, 2016
Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study
Martin E Gore, Robert J Jones, Alain Ravaud, et al.
European Urology
|
July 29, 2015
Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma
Camillo Porta, Martin E Gore, Brian I Rini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 20, 2011
Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus
James M G Larkin, Rosalie A Fisher, Lisa M Pickering, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 26, 2012
Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer
David S P Tan, Timothy A Yap, Margaret Hutka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 29, 2008
"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations
David S P Tan, Christian Rothermundt, Karen Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2013
Prognostic and predictive markers in metastatic renal cell carcinoma
Muhammad A Khattak, Farrah Bakr, Marcin Krzystanek, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 54) with videos related to
Sort By:
Page
of 6
Immunology
|
January 16, 2010
The melanocortin receptor agonist NDP-MSH impairs the allostimulatory function of dendritic cells
La'Verne P Rennalls, Thomas Seidl, James M G Larkin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2002
Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study
Ronald Bukowski, Marc S Ernstoff, Martin E Gore, et al.
Melanoma Research
|
March 29, 2006
Anti-alphaGal-dependent complement-mediated cytotoxicity in metastatic melanoma
James M G Larkin, Peter J Norsworthy, Roger P A'Hern, et al.
Gynecologic Oncology
|
July 7, 2007
Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials
Michelle L Harrison, Martin E Gore, David Spriggs, et al.
BJU International
|
December 17, 2016
Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study
Martin E Gore, Robert J Jones, Alain Ravaud, et al.
European Urology
|
July 29, 2015
Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma
Camillo Porta, Martin E Gore, Brian I Rini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 20, 2011
Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus
James M G Larkin, Rosalie A Fisher, Lisa M Pickering, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 26, 2012
Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer
David S P Tan, Timothy A Yap, Margaret Hutka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 29, 2008
"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations
David S P Tan, Christian Rothermundt, Karen Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2013
Prognostic and predictive markers in metastatic renal cell carcinoma
Muhammad A Khattak, Farrah Bakr, Marcin Krzystanek, et al.
Page
of 6